OCX - Oncocyte Corp Stock Price, Fair Value and News

2.95USD-0.12 (-3.91%)Delayed

Market Summary

USD2.95-0.12

Delayed

-3.91%

OCX Alerts

3 major insider buys recently.

OCX Stock Price

View Fullscreen

OCX RSI Chart

OCX Valuation

Market Cap

39.4M

Price/Earnings (Trailing)

-0.99

Price/Sales (Trailing)

28.53

EV/EBITDA

-0.88

Price/Free Cashflow

-2.22

OCX Price/Sales (Trailing)

OCX Profitability

Operating Margin

28.44%

EBT Margin

-2890.23%

Return on Equity

-344.69%

Return on Assets

-56.28%

Free Cashflow Yield

-45.06%

OCX Fundamentals

OCX Revenue

Revenue (TTM)

1.4M

Rev. Growth (Yr)

-97.05%

Rev. Growth (Qtr)

-43.95%

OCX Earnings

Earnings (TTM)

-39.9M

Earnings Growth (Yr)

-400.99%

Earnings Growth (Qtr)

42.92%

Breaking Down OCX Revenue

Last 7 days

2.1%

Last 30 days

13.9%

Last 90 days

-1.7%

Trailing 12 Months

-42.0%

How does OCX drawdown profile look like?

OCX Financial Health

Current Ratio

0.78

OCX Investor Care

Shares Dilution (1Y)

62.17%

Diluted EPS (TTM)

-5.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.4M	0	0	0
2023	6.5M	6.8M	7.1M	7.2M
2022	8.0M	6.2M	5.3M	2.0M
2021	2.3M	4.2M	4.6M	7.7M
2020	0	0	0	1.2M
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	293.0K
2016	0	0	0	0
2015	0	0	0	397.0K
2014	0	0	0	569.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Oncocyte Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	broadwood partners, l.p.	bought	7,057,690	2.9164	2,420,000	-
Apr 11, 2024	arno andrew	bought	99,999	2.95	33,898	-
Apr 11, 2024	riggs josh	bought	10,000	2.95	3,390	ceo and president
Apr 11, 2024	broadwood partners, l.p.	bought	-	-	-	-
Jun 30, 2023	gutfreund john peter	sold	-	-	-3,085,050	-
Jun 23, 2023	silverman lou	acquired	-	-	25,000	-
Jun 23, 2023	kingsley alfred d	acquired	-	-	20,000	-
Jun 23, 2023	last andrew j.	acquired	-	-	20,000	-
Jun 23, 2023	arno andrew	acquired	-	-	30,000	-
Jun 14, 2023	kingsley alfred d	bought	6,447	0.2149	30,000	-

Which funds bought or sold OCX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	reduced	-4.17	7.00	67.00	-%
May 16, 2024	AWM Investment Company, Inc.	unchanged	-	339,429	2,210,060	0.29%
May 15, 2024	STATE STREET CORP	unchanged	-	7,330	47,727	-%
May 15, 2024	MORGAN STANLEY	added	0.19	53,575	361,008	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-2.78	74.00	615	-%
May 15, 2024	PURA VIDA INVESTMENTS, LLC	reduced	-10.73	67,784	1,535,110	0.26%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-43.54	-2,816	5,508	-%
May 15, 2024	BROADWOOD CAPITAL INC	unchanged	-	1,078,900	7,351,560	0.55%
May 15, 2024	Royal Bank of Canada	reduced	-91.12	-2,000	-	-%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	1.00	3.00	-%

Are Funds Buying or Selling OCX?

Are funds buying OCX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OCX

No. of Funds

OCX Alerts

3 major insider buys recently.

Unveiling Oncocyte Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 22, 2024	bio-rad laboratories, inc.	8.99%	1,200,109	SC 13G
Apr 15, 2024	broadwood partners, l.p.	37.6%	0	SC 13D/A
Feb 14, 2024	pura vida investments, llc	8.45%	708,172	SC 13G/A
Feb 14, 2024	awm investment company, inc.	9.1%	754,286	SC 13G/A
Apr 14, 2023	pura vida investments, llc	9.99%	16,641,824	SC 13G/A
Apr 07, 2023	broadwood partners, l.p.	33.3%	0	SC 13D/A
Feb 14, 2023	pura vida investments, llc	15.22%	18,056,274	SC 13G
Feb 14, 2023	pura vida investments, llc	15.22%	18,056,274	SC 13G/A
Feb 14, 2023	awm investment company, inc.	6.10%	7,254,222	SC 13G
Nov 25, 2022	norfield capital llc	5.5%	6,600,359	SC 13G

Recent SEC filings of Oncocyte Corp

View All Filings

Date Filed	Form Type	Document
May 17, 2024	S-3/A	S-3/A
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 10, 2024	S-3	S-3
Apr 29, 2024	DEF 14A	DEF 14A
Apr 25, 2024	D	D
Apr 22, 2024	SC 13G	Major Ownership Report
Apr 16, 2024	10-K	Annual Report
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading

Peers (Alternatives to Oncocyte Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Oncocyte Corp News

Latest updates

Oncocyte Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-43.9%	176,000	314,000	429,000	463,000	5,959,000	274,000	67,000	237,000	1,424,000	3,589,000	984,000	2,030,000	1,124,000	503,000	555,000	143,000	-	-	-	-	-
Cost Of Revenue	-38.4%	252,000	409,000	159,000	169,000	265,000	278,000	314,000	183,000	105,000	2,220,000	860,000	1,350,000	738,000	716,000	601,000	365,000	173,000	-	-	-	-
Gross Profit	16.2%	-98,000	-117,000	248,000	272,000	10,000	-27,000	-269,000	31,000	247,000	2,601,000	-866,000	-394,000	79,000	-	-46,000	-222,000	-	-	-	-	-
Operating Expenses	-42.9%	9,169,000	16,062,000	6,761,000	8,566,000	-5,840,000	11,621,000	1,437,000	1,657,000	3,264,000	17,794,000	12,738,000	13,174,000	11,439,000	5,967,500	6,198,000	8,546,000	8,447,000	7,523,000	5,257,000	5,462,000	3,997,000
S&GA Expenses	45.4%	846,000	582,000	713,000	805,000	695,000	334,000	405,000	127,000	266,000	3,309,000	2,931,000	2,673,000	2,254,000	1,874,000	1,568,000	1,562,000	1,490,000	1,011,000	630,000	318,000	205,000
R&D Expenses	-14.8%	2,169,000	2,547,000	2,185,000	2,435,000	2,127,000	1,378,000	1,472,000	2,444,000	2,007,000	4,591,000	3,142,000	2,537,000	3,361,000	1,800,000	2,615,000	3,225,000	2,159,000	2,318,000	1,625,000	1,508,000	1,343,000
EBITDA Margin	-756.9%	-27.87	-3.25	-2.68	-2.15	-1.17	-8.59	-7.74	-8.55	-8.03	-9.41	-9.43	-8.77	-14.59	-	-	-	-	-	-	-	-
Interest Expenses	100.0%	-	-160,000	117,000	1,000	-10,000	-18,000	-14,000	-21,000	-30,000	-42,000	-50,000	-49,000	-68,000	-77,000	-78,000	-75,000	-22,000	16,500	135,000	167,000	-19,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-97,000	-	-1,794,000	-7,564,000	159,000	-	-2,190,000	1,095,000	-	-	-	-
Earnings Before Taxes	42.9%	-9,129,000	-15,992,000	-6,489,000	-8,333,000	5,959,000	-12,017,000	-1,818,000	-1,364,000	-3,413,000	-35,788,000	-13,800,000	-12,287,000	-11,483,000	-6,468,000	-6,783,000	-9,108,000	-8,827,000	-7,954,000	-5,225,000	-5,383,000	-3,864,000
EBT Margin	-733.2%	-28.90	-3.47	-2.93	-2.40	-1.41	-9.30	-7.97	-8.72	-8.13	-9.49	-9.49	-8.79	-14.56	-	-	-	-	-	-	-	-
Net Income	42.9%	-9,129,000	-15,992,000	-6,489,000	-8,333,000	3,033,000	-44,978,000	-9,333,000	-8,300,000	-10,291,000	-35,885,000	-13,800,000	-10,493,000	-3,919,000	-6,309,000	-6,783,000	-9,108,000	-7,732,000	-7,954,000	-5,225,000	-5,383,000	-3,864,000
Net Income Margin	-645.4%	-28.90	-3.88	-7.97	-8.81	-9.11	-36.41	-12.00	-10.95	-8.78	-8.30	-6.11	-4.95	-7.37	-	-	-	-	-	-	-	-
Free Cashflow	20.1%	-3,854,000	-4,826,000	-2,259,000	-6,832,000	-9,672,000	-10,450,000	-12,255,000	-12,365,000	-14,838,000	-7,466,000	-11,377,000	-8,668,000	-10,677,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-5.2%	71.00	75.00	82.00	88.00	83.00	100	157	171	146	160	168	177	129	55.00	58.00	63.00	60.00	40.00	33.00	38.00	42.00
Current Assets	-38.9%	7.00	11.00	17.00	21.00	16.00	26.00	37.00	49.00	25.00	39.00	48.00	50.00	63.00	9.00	12.00	18.00	18.00	23.00	20.00	37.00	41.00
Cash Equivalents	-40.6%	6.00	9.00	14.00	17.00	12.00	20.00	32.00	45.00	20.00	33.00	43.00	47.00	59.00	7.00	10.00	17.00	17.00	22.00	19.00	36.00	39.00
Net PPE	14.7%	5.00	5.00	-	-	5.00	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00
Goodwill	-	-	-	-	-	-	-	19.00	19.00	19.00	19.00	18.00	24.00	9.00	9.00	9.00	9.00	9.00	-	-	-	-
Liabilities	9.6%	54.00	49.00	39.00	39.00	39.00	60.00	75.00	83.00	89.00	94.00	69.00	75.00	5.00	22.00	23.00	24.00	23.00	9.00	3.00	4.00	3.00
Current Liabilities	15.7%	8.00	7.00	8.00	8.00	9.00	12.00	13.00	14.00	14.00	14.00	13.00	20.00	10.00	9.00	9.00	7.00	7.00	4.00	3.00	4.00	3.00
Shareholder's Equity	-43.4%	12.00	20.00	38.00	44.00	38.00	34.00	77.00	83.00	57.00	65.00	99.00	103	107	33.00	35.00	40.00	37.00	31.00	29.00	34.00	38.00
Retained Earnings	-3.1%	-299	-289	-272	-265	-257	-260	-215	-206	-198	-187	-151	-138	-127	-123	-117	-110	-101	-93.74	-85.79	-80.57	-75.18
Shares Outstanding	0.1%	8.00	8.00	8.00	8.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	4.00	4.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	19.00	-	-	-	69.00	-	-	-	298	-	-	-	70.00	-	-	-	47.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	16.0%	-3,830	-4,562	-2,259	-6,832	-9,672	-9,648	-11,396	-11,247	-13,277	-7,065	-10,983	-8,058	-9,835	-6,144	-6,005	-6,961	-6,870	-5,306	-4,851	-2,840	-6,718
Share Based Compensation	-13.6%	418	484	608	834	834	2,619	3,181	2,232	2,010	1,705	1,850	1,996	1,290	985	1,784	1,361	937	787	821	701	686
Cashflow From Investing	-110.0%	-24.00	241	-1,296	1,495	-1,372	-802	-859	-1,118	-1,561	-401	-394	-4,894	-8,272	-498	-526	-4,533	-6,191	-1,216	-11,235	-11.00	47.00
Cashflow From Financing	100.0%	-	-30.00	-30.00	12,274	-28.00	-100	-528	36,789	-355	-269	8,215	547	69,871	3,493	28.00	11,713	7,565	10,850	-296	-580	37,894

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OCX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Income Statement [Abstract]

Net revenue

$ 176,000

$ 297,000

Cost of revenues

252,000

265,000

Cost of revenues – amortization of acquired intangibles

22,000

Gross (loss) profit

(98,000)

10,000

Operating expenses:

Research and development

2,169,000

2,127,000

Sales and marketing

846,000

695,000

General and administrative

2,673,000

3,412,000

Change in fair value of contingent consideration

3,312,000

(18,307,000)

Impairment loss

4,950,000

Impairment loss on held for sale assets

169,000

1,283,000

Total operating expenses (credits)

9,169,000

(5,840,000)

(Loss) income from operations

(9,267,000)

5,850,000

Other (expenses) income:

Interest expense

(15,000)

(11,000)

Unrealized gain on marketable equity securities

121,000

Other income (expenses), net

153,000

(1,000)

Total other income

138,000

109,000

(Loss) income before income taxes

(9,129,000)

5,959,000

Income taxes

(Loss) income from continuing operations

(9,129,000)

5,959,000

Loss from discontinued operations (Note 11)

(2,926,000)

Net (loss) income

(9,129,000)

3,033,000

Net (loss) income per share:

Net (loss) income from continuing operations - basic

^[1]

(9,335)

4,899

Net (loss) income from continuing operations - diluted

^[1]

(9,335)

4,899

Net loss from discontinued operations - basic

^[1]

(2,502)

Net loss from discontinued operations - diluted

^[1]

(2,502)

Net (loss) income attributable to common stockholders - basic

^[1]

(9,335)

2,397

Net (loss) income attributable to common stockholders - diluted

^[1]

$ (9,335)

$ 2,397

Net (loss) income from continuing operations per share - basic

$ (1.13)

$ 0.82

Net (loss) income from continuing operations per share - diluted

(1.13)

0.82

Net loss from discontinued operations per share - basic

(0.42)

Net loss from discontinued operations per share - diluted

(0.42)

Net (loss) income attributable to common stockholders per share - basic

(1.13)

0.40

Net (loss) income attributable to common stockholders per share - diluted

$ (1.13)

$ 0.40

Weighted average shares outstanding - basic

8,264

5,958

Weighted average shares outstanding - diluted

8,264

5,963

[1]	The additional 2023 dilutive adjustments for undistributed earnings/losses allocated to participating securities had no impact on income (loss) or the resulting diluted per share calculations.

OCX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 5,578	$ 9,432
Accounts receivable, net of allowance for credit losses of $2 and $5, respectively	161	484
Prepaid expenses and other current assets	735	643
Assets held for sale	61	139
Total current assets	6,535	10,698
NONCURRENT ASSETS
Right-of-use and financing lease assets, net	2,199	1,637
Machinery and equipment, net, and construction in progress	3,528	3,799
Intangible assets, net	56,573	56,595
Restricted cash	1,700	1,700
Other noncurrent assets	438	463
TOTAL ASSETS	70,973	74,892
CURRENT LIABILITIES
Accounts payable	908	953
Accrued compensation	2,427	1,649
Accrued royalties	1,116	1,116
Accrued expenses and other current liabilities	741	452
Accrued severance from acquisition	2,314	2,314
Right-of-use liabilities, current	821	665
Current liabilities of discontinued operations (Note 11)		45
Total current liabilities	8,327	7,194
NONCURRENT LIABILITIES
Right-of-use liabilities, noncurrent	2,514	2,204
Contingent consideration liabilities	43,212	39,900
TOTAL LIABILITIES	54,053	49,298
Commitments and contingencies (Note 6)
Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 shares issued and outstanding at March 31, 2024 and December 31, 2023; aggregate liquidation preference of $5,376 and $5,296 as of March 31, 2024 and December 31, 2023, respectively	5,332	5,126
SHAREHOLDERS’ EQUITY
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding
Common stock, no par value, 230,000 shares authorized; 8,273 and 8,261 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	310,553	310,295
Accumulated other comprehensive income	40	49
Accumulated deficit	(299,005)	(289,876)
Total shareholders’ equity	11,588	20,468
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 70,973	$ 74,892

About Oncocyte Corp

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

CEO	Mr. Joshua Riggs
WEBSITE	https://oncocyte.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	75

Oncocyte Corp Frequently Asked Questions

What is the ticker symbol for Oncocyte Corp? What does OCX stand for in stocks?

OCX is the stock ticker symbol of Oncocyte Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oncocyte Corp (OCX)?

As of Fri May 17 2024, market cap of Oncocyte Corp is 39.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCX stock?

You can check OCX's fair value in chart for subscribers.

What is the fair value of OCX stock?

You can check OCX's fair value in chart for subscribers. The fair value of Oncocyte Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Oncocyte Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Oncocyte Corp a good stock to buy?

The fair value guage provides a quick view whether OCX is over valued or under valued. Whether Oncocyte Corp is cheap or expensive depends on the assumptions which impact Oncocyte Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCX.

What is Oncocyte Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OCX's PE ratio (Price to Earnings) is -0.99 and Price to Sales (PS) ratio is 28.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCX PE ratio will change depending on the future growth rate expectations of investors.